VRCA - Why Is Skin Disease-Focused Verrica Pharmaceuticals Stock Trading Higher Today? | Benzinga
Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) development and commercialization partner, Torii Pharmaceutical Co Ltd, reported topline results from its Phase 3 trial of TO-208 (referred to as VP-102 and marketed as Ycanth in the U.S.) for the treatment of Molluscum Contagiosum in Japan.
Molluscum Contagiosum is a common skin infection caused by a virus. The Phase 3 trial was conducted in Japan to evaluate ...